Skip to main content
Equibles
GNLX logo

GNLX · GENELUX Corp

Track GNLX — free

Use GNLX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GNLX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.73 +0.01 (+0.37%) At close · Aug 26
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has experienced recurring losses from operations since inception and incurred a net loss of $18.4 million and cash used in operations of $12.5 million during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$123.07M
Shares
45.25M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.73 Open$2.73 Day$2.64–2.76 52W close$2.30–8.24 Avg vol 30d288K Short int3.5M · 7.8% float · 8.5d Short vol48% DataJan 2023–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −4%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −4%
trailing
6-month return +1%
trailing
YTD return −37%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +11 funds added
Insider flow Distributing
Net -$48.2K over 90 days · 100% sells
Short interest Rising
7.78% of float · ▲ +14.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
72 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Fair
Revenue growth 0%
Y/Y
EPS growth +9%
Y/Y
Free cash flow $-26.4M
Balance sheet $4.6M
net debt
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −72%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +11 funds added
Insider flow Distributing
Net -$48.2K over 90 days · 100% sells
Short interest Rising
7.78% of float · ▲ +14.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
72 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 7% Range high $8
vs 200-day avg -14% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GNLX
GENELUX Corp
this stock
$123.07M -37.4% +0.0% — 7.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.7% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +5.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $63.81B +24.5% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
72
% held
21.7%
Net QoQ
+496.5K sh
Top holder
WOODWARD DIVERSIFIED CAPI…
Held Float
View
Held by Funds
Fund positions
18
View
Short & Settlement
Short Interest Rising
Shares short
3.5M
Days to cover
8.5d
Change
+434.5K sh
View
Short Volume
Short vol %
48%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
15.1K
Value
$42.9K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
48.2%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$48.2K
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$8.0K
Net income (FY)
$-32.1M
EPS diluted
$-0.86
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 13, 2026
This year
10
View
Proposed Sales
Value
$34.9K
Shares
12.0K
Filed
Jul 1, 2026
View
Exempt Offerings
Offering
$18.0M
Filed
Jun 29, 2023
View

Performance

5D 20D 120D MTD YTD
GNLX +1.9% -3.5% +1.5% -7.1% -37.4%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY +2.3% -8.6% -11.0% -9.7% -49.7%
Key facts CIK 1231457 CUSIP 36870H103 13F (30d) 59 filings 58 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)